GlassScriptPhysician profile
Victoria Wong
NPI 1437693918
$51,400.28
in general payments reported to CMS, 2019-2025
23 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $11K · 2023: $17K · 2024: $3,983 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $4,702 · Consulting Fee: $4,155 · Travel and Lodging: $981 · Honoraria: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,006.25 |
| Food and Beverage | $4,701.51 |
| Consulting Fee | $4,155.00 |
| Travel and Lodging | $980.96 |
| Honoraria | $780.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $33,896.92 | 2022-2025 | Erleada, Rybrevant, Carvykti |
| Exelixis INC. | $11,681.41 | 2021-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $1,150.85 | 2021-2025 | |
| Pfizer INC. | $959.26 | 2021-2025 | |
| Seagen INC. | $927.36 | 2021-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $825.04 | 2021-2025 | Tagrisso, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $429.17 | 2021-2023 | Opdivo |
| Daiichi Sankyo INC. | $272.73 | 2021-2025 | Vanflyta, Enhertu |
| Gilead Sciences, INC. | $234.22 | 2022-2025 | Trodelvy |
| Myovant Sciences INC. | $195.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $147.24 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $143.79 | 2022-2025 | Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $134.22 | 2022-2025 | |
| Genzyme Corporation | $100.79 | 2022-2023 | |
| Eisai INC. | $88.40 | 2021-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $40.70 | 2023 | Krazati |
| Biohaven Pharmaceuticals, INC. | $37.92 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $29.77 | 2023 | Imbruvica |
| Sumitomo Pharma America, INC. | $28.87 | 2024 | Orgovyx |
| Tolmar Pharmaceuticals, INC. | $27.92 | 2021 | |
| Genmab U.S., INC. | $16.40 | 2024 | Tivdak |
| Regeneron Healthcare Solutions, INC. | $16.25 | 2025 | Libtayo |
| Clovis Oncology, INC. | $15.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.